Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related differences in outcomes and tumor characteristics of ultra-rare sarcomas: A Nation-wide Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.

Therapeutic advances in medical oncology·2025
Same author

Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.

Cancer medicine·2024
Same author

Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women.

Breast cancer research and treatment·2024
Same journal

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

ESMO open·2026
Same journal

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

ESMO open·2026
Same journal

ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer.

ESMO open·2026
Same journal

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026
Same journal

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.

ESMO open·2026
Same journal

Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years.

ESMO open·2026
See all related articles

Related Experiment Video

Updated: Dec 27, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

Genomic-guided precision therapy for soft tissue sarcoma.

Hsing-Wu Chen1,2, Tom Wei-Wu Chen3

  • 1Department of Oncology, National Taiwan University Hospital Yunlin Branch, Douliou, Yunlin, Taiwan.

ESMO Open
|March 6, 2020
PubMed
Summary
This summary is machine-generated.

Genomic alterations in soft tissue sarcoma (STS) are driving new targeted therapies. Molecular diagnosis and next-generation sequencing enable personalized, genomic-guided treatment for advanced STS patients.

Keywords:
genomicsprecision medicinesarcoma

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.5K

Related Experiment Videos

Last Updated: Dec 27, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.5K

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Soft tissue sarcoma (STS) is a heterogeneous cancer, historically treated uniformly with chemotherapy.
  • Recent advances in understanding STS genomics have led to the development of targeted therapies.
  • Molecularly targeted agents have begun to reshape treatment paradigms for advanced STS.

Purpose of the Study:

  • To review the progress of genomic-guided therapy for soft tissue sarcoma.
  • To highlight tailored treatments based on specific molecular alterations in different STS histologies.
  • To discuss the impact of molecular diagnosis and next-generation sequencing on STS treatment.

Main Methods:

  • Review of clinical studies validating small-molecule inhibitors.
  • Analysis of genomic alterations in various STS histologies.
  • Discussion of emerging therapeutic targets and epigenetic regulators.

Main Results:

  • Small-molecule inhibitors targeting c-KIT, PDGFRA, c-MET, BRAF, ALK, ROS1, and CSF1R have shown practice-changing results.
  • Several molecularly targeted agents have been successfully validated in clinical trials.
  • Genomic-based therapeutic approaches are becoming increasingly applicable.

Conclusions:

  • A genomic-guided therapeutic approach is crucial for advanced STS.
  • Personalized medicine based on molecular alterations is transforming STS treatment.
  • Future development of inhibitors for novel genomic targets will further advance STS care.